Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction

New England Journal of Medicine

Volumn 339, Issue 8, 1998, Pages 489-497

  Gottlieb, Stephen S ^a   McCarter, Robert J ^b   Vogel, Robert A ^b  

^a UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGE; AGED; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CAUCASIAN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CREATININE BLOOD LEVEL; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEGRO; PRIORITY JOURNAL; RACE DIFFERENCE;

ADRENERGIC BETA-ANTAGONISTS; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; AGED; AGED, 80 AND OVER; CARDIAC OUTPUT, LOW; DIABETES COMPLICATIONS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; LUNG DISEASES; MALE; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RISK; SURVIVAL ANALYSIS;

EID: 0032552240     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199808203390801     Document Type: Article

References (36)

1. β-Blocker Heart Attack Study Group. The β-Blocker Heart Attack Trial. JAMA 1981;246:2073-4.
2. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-7
3. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 1981;2:823-7.
4. Ellerbeck EF, Jencks SF, Radford MJ, et al. Quality of care for Medicare patients with acute myocardial infarction: a four state pilot study from the Cooperative Cardiovascular Project. JAMA 1995;273:1509-14.
5. Brand DA, Newcomer LN, Freiburger A, Tian H. Cardiologists' practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction. J Am Coll Cardiol 1995;26:1432-6.
6. Viskin S, Kitzis I, Lev E, et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol 1995;25:1327-32.
7. Marciniak TA, Ellerbeck EF, Radford MJ, et al. Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. JAMA 1998;279:1351-7.
8. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
9. Killip T III, Kimball JT. Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients. Am J Cardiol 1967; 20:457-64.
10. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA 1988;260:2088-93.
11. β-Blocker Heart Attack Study Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982;247:1707-14.
12. Committee on Management of Acute Myocardial Infarction. ACC/AHA Guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol 1996;28:1328-428.
13. Anderson JL. Medical therapy for elderly patients who have had myocardial infarction: too little to the late in life? Ann Intern Med 1996;124:335-8.
14. Aronow WS. Prevalence of use of beta blockers and of calcium channel blockers in older patients with prior myocardial infarction at the time of admission to a nursing home. J Am Geriatr Soc 1996;44:1075-7.
15. Gundersen T, Abrahamsen AM, Kjekshus J, Ronnevik PK. Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction. Circulation 1982;66:1179-84.
16. Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of β-blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277:115-21.
17. Zuanetti G, Latini R, Maggioni AP, Santoro L, Franzosi MG. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol 1993;22:1788-94.
18. Kjekshus J, Gilpin E, Cali G, Blackey AR, Henning H, Ross J Jr. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990;11:43-50.
19. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann Intern Med 1997;126:955-9.
20. Gundersen T, Kjekshus J. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care 1983;6:285-90.
21. Malmberg K, Herlitz J, Hjalmarson A, Ryden L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction: retrospective data from two large studies. Eur Heart J 1989; 10:423-8.
22. Tattersfield AE. Respiratory function in the elderly and the effects of beta blockade. Cardiovasc Drugs Thcr 1991;4:Suppl 6:1229-32.
23. Woolcock AJ, Anderson SD, Peat JK, et al. Characteristics of bronchial hyperresponsiveness in chronic obstructive pulmonary disease and in asthma. Am Rev Respir Dis 1991;143:1438-43.
24. Gold MR, Dec GW, Cocca-Spoftbrd D, Thompson BT. Esmolol and ventilatory function in cardiac patients with COPD. Chest 1991;100:1215-8.
25. Fogari R, Zoppi A, Tettamanti F, Poletti L, Rizzardi G, Fiocchi G. Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease. Cardiovasc Drugs Ther 1990;4:1145-9.
26. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
27. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6.
28. CIBIS Investigators and Committees. A randomized trial of β-block-ade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-73.
29. Woodley SL, Gilbert EM, Anderson JL, et al. β-Blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:2426-41.
30. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503-10.
31. Becker RC. Beta-adrenergic blockade following thrombolytic therapy: is it helpful or harmful? Clin Cardiol 1994;17:171-4.
32. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 1991;83:422-37.
33. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993;328:914-21. [Erratum, N Engl J Med 1994;330:1689.]
34. Prisant LM, Mensah GA. Use of beta-adrenergic receptor blockers in blacks. J Clin Pharmacol 1996;36:867-73.
35. Johnson JA, Burlew BS, Stiles RN. Racial differences in beta-adrenoceptor-mediated responsiveness. J Cardiovasc Pharmacol 1995;25:90-6.
36. Haywood LJ. Coronary heart disease mortality/morbidity and risk in blacks. I. Clinical manifestations and diagnostic criteria: the experience with the Beta Blocker Heart Attack Trial. Am Heart J 1984;108:787-93.